2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

2:30PM-4:00PM: Abstract Number: 1966

Antibodies Against Domain 1 and Domain 4/5 of β2 Glycoprotein I: Clinical Relevance in Obstetric Anti-Phospholipid Syndrome

Antiphospholipid Syndrome

2:30PM-4:00PM: Abstract Number: 1965

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: First and Recurrent Thrombosis Risk after 720 Patient-Years of Follow-up

Antiphospholipid Syndrome

2:30PM-4:00PM: Abstract Number: 1962

Antiphospholipid Syndrome Neutrophils Are Characterized By Overexpression of P-Selectin Glycoprotein Ligand 1, a Potential Therapeutic Target

Antiphospholipid Syndrome

2:30PM-4:00PM: Abstract Number: 1994

Associations of Chronic Lung Comorbidity with Medications, Disease Activity, and All-Cause Mortality in Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects II: Risk and Impact of Comorbidity

2:30PM-4:00PM: Abstract Number: 2013

BIIB059, a Monoclonal Antibody Targeting BDCA2, Shows Evidence of Biological Activity and Early Clinical Proof of Concept in Subjects with Active Cutaneous SLE

Systemic Lupus Erythematosus – Clinical Aspects and Treatment III: Novel and Current Therapies

2:30PM-4:00PM: Abstract Number: 1999

Claims-Based Analysis of Cost-Effectiveness Among Patients with Rheumatoid Arthritis Who Switched from a Tumor Necrosis Factor Inhibitor to Another Targeted Disease-Modifying Antirheumatic Drug

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy II: Safety and Cost Effectiveness

2:30PM-4:00PM: Abstract Number: 1982

Comparative Safety of Long-Acting Opioids for Non-Cancer Pain

Pain – Basic and Clinical Aspects

2:30PM-4:00PM: Abstract Number: 1972

Creatine Kinase in the United States Population: Impact of Demographics, Comorbidities and Body Composition on the Normal Range

Healthcare Disparities in Rheumatology

2:30PM-4:00PM: Abstract Number: 1967

Depression Is a Risk Factor for Low Treatment Adherence in African American People with Systemic Lupus Erythematosus

Healthcare Disparities in Rheumatology

2:30PM-4:00PM: Abstract Number: 2022

Developing a Gout Needs Assessment Incorporating Patient Perspective on Self-Management, Self-Efficacy and Disease Specific Knowledge, to Inform a Patient Education Initiative

ARHP III: Education and Community Programs

2:30PM-4:00PM: Abstract Number: 2021

Development of an Item Bank on Disease and Treatment Associated Knowledge of Rheumatoid Arthritis to Improve Patient Engagement in Care

ARHP III: Education and Community Programs

2:30PM-4:00PM: Abstract Number: 2002

Differences in Features of Chronic Back Pain in First Degree Relatives of Patients with Ankylosing Spondylitis (AS) Compared to the U.S. Population

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment III: Axial Spondyloarthritis – Clinical

2:30PM-4:00PM: Abstract Number: 1978

Differential Pattern of Doppler Signals at Lower Extremity Entheses of Healthy Children

Imaging of Rheumatic Diseases II: Ultrasound in Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 1970

Disparities in Access to Specialist Care at the Time of Diagnosis of Systemic Lupus Erythematosus

Healthcare Disparities in Rheumatology

2:30PM-4:00PM: Abstract Number: 2024

Effect of a Revised Counselor Training on Skills Development and Knowledge of Volunteers with Systemic Lupus Erythematosus

ARHP III: Education and Community Programs

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].